アデノシン5'-[二りん酸P2-[1-(1,4-ジヒドロ-3-カルバモイルピリジン-1-イル)-1,5-ジデオキシ-β-D-ribo-ペントフラノース-5-イル]]

Nadh

HCID 439153CAS 58-68-4

基本情報

標準SMILES
NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1
InChIKey
BOPGDPNILDQYTO-NNYOXOHSSA-N
分子式
C21H29N7O14P2
平均分子量
665.4 g/mol
単同位体質量
665.12477262

名称と識別子

優先名称
Nadh
IUPAC
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
現地名
アデノシン5'-[二りん酸P2-[1-(1,4-ジヒドロ-3-カルバモイルピリジン-1-イル)-1,5-ジデオキシ-β-D-ribo-ペントフラノース-5-イル]]
英語名
dihydrodiphosphopyridine nucleotide
分子式
C21H29N7O14P2
分子量
665.44

名称と別名

NADHDPNHbeta-NADH58-68-41,4-Dihydronicotinamide adenine dinucleotideNADH2dihydronicotinamide adenine dinucleotideReduced nicotinamide adenine diphosphateReduced nicotinamide-adenine dinucleotideReduced Nicotinamide Adenine Dinucleotide[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate4J24DQ0916
名称をさらに表示
ジヒドロニコチンアミドアデニンジヌクレオチド還元ニコチンアミドアデニンジヌクレオチドジヒドロニコチンアミドモノヌクレオチド還元型ニコチンアミドアデニンジヌクレオチド還元型コデヒドロゲナーゼIアデノシン5'-[二りん酸P2-[1-(1,4-ジヒドロ-3-カルバモイルピリジン-1-イル)-1,5-ジデオキシ-β-D-ribo-ペントフラノース-5-イル]]ジヒドロコジマーゼ還元ニコチンアミドアデニン二りん酸ジヒドロコデヒドロゲナーゼI1-[5-O-(5'-アデニリルオキシホスホニル)-β-D-リボフラノシル]-1,4-ジヒドロニコチンアミド還元型補発酵素還元型コデヒドラーゼI還元型CoI還元型補酵素Iアデノシン5'-[二りん酸β-[1-(3-カルバモイル-1,4-ジヒドロピリジン-1-イル)-1,5-ジデオキシ-β-D-リボフラノース-5-イル]]還元型コエンザイムI1,4-ジヒドロニコチンアミドアデニンジヌクレオチド還元ジホスホピリジンヌクレオチド還元型ジホスホピリジンヌクレオチド還元コデヒドロゲナーゼINICOTINAMIDE ADENINE DINUCLEOTIDEdihydrocozymaseReduced formβ-NADH, DPNH, NADHReduced codehydrase ITestosterone 17β-dehydrogenase
Nicotinamide-adenine dinucleotide, reducednicotinamide adenine dinucleotide (reduced)CHEBI:16908DTXSID30889320[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acidAdenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamideNAD reduced(((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl)methoxy)(hydroxy)phosphoryl)oxy)((((2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl)methoxy))phosphinic acid

データベース識別子

CAS
58-68-4、606-68-8
PubChem CID
439153
DTXSID
DTXSID30889320
ChEMBL
CHEMBL1234616
ChEBI
CHEBI:16908
UNII
4J24DQ0916
EC Number
200-393-0
Nikkaji
J213.546I

物性

構造計算による物性

XLogP
-5.7
極性表面積
318 Ų
水素結合供与体数
8
水素結合受容体数
19
回転可能結合数
11
重原子数
44

実験および物理化学的性質

LogP-5.1
Melting Point · 2 件

140.0-142.0 °C

140.0 - 142.0 °C

Physical DescriptionSolid

物理化学的性質

沸点
1081.8 · 1081.8±75.0 °C(Predicted)
比重(密度)
2.18 · 2.18±0.1 g/cm3(Predicted)
溶解性
Water (Slightly)
酸解離定数(Pka)
1.13 · 1.13±0.50(Predicted)
外見
Solid
色
White to Off-White

安全と法規制

危険有害性情報

Regulatory Information · 2 件

Chemical: Adenosine 5′-(trihydrogen diphosphate), P′.fwdarw.5′-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide

Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationEvaluation - Chemicals that are unlikely to require further regulation to manage risks to environment

法規制情報

Regulatory Information · 2 件

Chemical: Adenosine 5′-(trihydrogen diphosphate), P′.fwdarw.5′-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide

Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard

安全データ

tsca
TSCA listed

化学と産業

薬理情報

Pharmacodynamics · 1 件

A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes.

Mechanism of Action · 1 件

NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.

Absorption, Distribution and ExcretionUnclear how much of an administered dose is absorbed.
Tissue LocationsBladder;Brain;Fibroblasts;Platelet;Skeletal Muscle
Cellular LocationsEndoplasmic reticulum;Mitochondria;Peroxisome
Metabolite Pathways · 1 件

11-beta-hydroxylase deficiency (CYP11B1);17-alpha-hydroxylase deficiency (CYP17);17-Beta Hydroxysteroid Dehydrogenase III Deficiency;2-aminoadipic 2-oxoadipic aciduria;2-Hydroxyglutric Aciduria (D And L Form);2-ketoglutarate dehydrogenase complex deficiency;2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);27-Hydroxylase Deficiency;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;Total 46220 pathways, visit the HMDB page for details

用途と製造

General Manufacturing InformationAdenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide: INACTIVE

サプライヤー24 社

weifang runzhong fine chemical co., ltd536-7868377 +8618653686003 · [email protected]
曼顿生物科技(深圳)有限公司+86-75589664337 +86-15112661142 · [email protected]
湖南瑞威尔生物科技有限公司15608648206 13297919155 · [email protected]
北京博奥森生物技术有限公司400-901-9800 18611424007 · [email protected]
上海梅凯科技有限公司021-68689288 15300790979 · [email protected]

補足説明

定義ChEBI: A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide.

関連反応

141 件

関連ノート

読み込み中…